Go Deep
Helix BioPharma Corp.
Helix BioPharma Corp. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,486 | -26.0 | 5.41 | 0.03 | 70.68 |
| Oct 2026 | 20,714 | -24.8 | 5.15 | 0.03 | 66.97 |
Helix BioPharma Corp. Quarterly Results
| Line Item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -671,000.0 | -694,000.0 | -1,008,000.0 | — |
| EPS | -0.0 | -0.0 | -0.0 | — |
Helix BioPharma Corp. Revenue & Profit: Last 4 Years
| Line Item | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|
| Revenue | — | 0.0 | 0.0 | 0.0 |
| Net Profit | — | -9,264,000.0 | -6,290,000.0 | -6,563,000.0 |
| EPS | -0.1 | -0.2 | -0.2 | -0.2 |
Helix BioPharma Corp. Balance Sheet
| Line Item | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|
| Total Assets | 1,489,000.0 | 1,029,000.0 | 3,731,000.0 |
| Total Liabilities | 1,579,000.0 | 1,874,000.0 | 3,412,000.0 |
| Total Equity | -90,000.0 | -845,000.0 | 319,000.0 |
Owes vs Owns
Helix BioPharma Corp. owed C$0.31 for every C$1 it owned in Apr 2026, down from C$0.91 in Jul 2022.
| Period | Apr 2026 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|
| Owes vs Owns | 0.31× | 1.06× | 1.82× | 0.91× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Helix BioPharma Corp. Assets & Liabilities Breakdown (CAD millions)
What it owns — Jul 2024
Cash & short-term investments 72.6%Receivables 3.6%Fixed assets (tangible) 2.2%Other assets 21.6%
How it's funded — Jul 2024
Payables 54.1%Other liabilities 45.9%
| Line Item | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | 1.1 | 0.8 | 3.3 |
| Receivables | 0.1 | 0.1 | 0.3 |
| Inventory | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 |
| Other assets | 0.3 | 0.1 | 0.2 |
| Liabilities & equity | |||
| Short-term debt | 0.0 | 0.0 | 2.5 |
| Long-term debt | 0.0 | 0.0 | 0.0 |
| Payables | 0.9 | 0.5 | 0.6 |
| Other liabilities | 0.7 | 1.4 | 0.3 |
| Shareholders' equity | -0.1 | -0.8 | 0.3 |
| Net tangible assets | -0.1 | -0.8 | 0.3 |
Helix BioPharma Corp. Cash Flow
| Line Item | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|
| Operating Activities | -5,219,000.0 | -5,526,000.0 | -6,509,000.0 |
| Investing Activities | -14,000.0 | -5,000.0 | 0.0 |
| Financing Activities | 5,506,000.0 | 3,087,000.0 | 6,205,000.0 |